Azole Binding Properties of Candida albicans Sterol 14-α Demethylase (CaCYP51)
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Purified Candida albicans sterol 14-α demethylase (CaCYP51) bound the CYP51 substrates lanosterol and eburicol, producing type I binding spectra with K s values of 11 and 25 μM, respectively, and a K m value of 6 μM for lanosterol. Azole binding to CaCYP51 was “tight” with both the type II spectral intensity (Δ A max ) and the azole concentration required to obtain a half-Δ A max being proportional to the CaCYP51 concentration. Tight binding of fluconazole and itraconazole was confirmed by 50% inhibitory concentration determinations from CYP51 reconstitution assays. CaCYP51 had similar affinities for clotrimazole, econazole, itraconazole, ketoconazole, miconazole, and voriconazole, with K d values of 10 to 26 μM under oxidative conditions, compared with 47 μM for fluconazole. The affinities of CaCYP51 for fluconazole and itraconazole appeared to be 4- and 2-fold lower based on CO displacement studies than those when using direct ligand binding under oxidative conditions. Econazole and miconazole were most readily displaced by carbon monoxide, followed by clotrimazole, ketoconazole, and fluconazole, and then voriconazole (7.8 pmol min −1 ), but itraconzole could not be displaced by carbon monoxide. This work reports in depth the characterization of the azole binding properties of wild-type C. albicans CYP51, including that of voriconazole, and will contribute to effective screening of new therapeutic azole antifungal agents. Preliminary comparative studies with the I471T CaCYP51 protein suggested that fluconazole resistance conferred by this mutation was through a combination of increased turnover, increased affinity for substrate, and a reduced affinity for fluconazole in the presence of substrate, allowing the enzyme to remain functionally active, albeit at reduced velocity, at higher fluconazole concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Point mutations in the ERG11 gene result in reduced binding affinity of azoles to their target without precluding enzymatic function (31).”
From Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans (2012) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82244-3 · Cited by 11,781
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 1×
“albicans strains and other Candida species has become an increasing problem, especially among hospitalized immunocompromised patients, such as HIV and AIDS, cancer, and transplant patients, leading to a growing need to develop new effective antifungal strategies against drug-resistant strains (41, 45, 49).”
BackgroundThe Carbon Monoxide-binding Pigment of Liver Microsomes
Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82245-5 · Cited by 3,489
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814 · cited 4×
“The data were fitted using the Morrison equation (37), including a vertical offset constant where appropriate to determine the apparent Kd values.”
BackgroundMethodInfluentialPodust, L. M., Poulos, T. L., & Waterman, M. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061562898 · Cited by 531 · cited 2×
“The I471T residue lies in the cysteine pocket behind the plane of the heme and therefore cannot directly interact with the substrate or inhibitor (44).”
BackgroundChanging patterns and trends in systemic fungal infections
Richardson, M. D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki218 · Cited by 525 · cited 1×
“albicans strains and other Candida species has become an increasing problem, especially among hospitalized immunocompromised patients, such as HIV and AIDS, cancer, and transplant patients, leading to a growing need to develop new effective antifungal strategies against drug-resistant strains (41, 45, 49).”
BackgroundSterol 14α-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms
Lepesheva, G. I., & Waterman, M. R. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.07.018 · Cited by 474 · cited 1×
“This network would strengthen the water-iron coordination, explaining why CYP51 proteins are found predominantly in the low-spin form (29) and why CYP51 proteins undergo only a partial low- to high-spin transition during substrate binding.”
BackgroundSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465 · cited 1×
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
BackgroundMarichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382 · cited 1×
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
BackgroundJefcoate, C. R. (1978) · Methods in Enzymology · doi:10.1016/s0076-6879(78)52029-6 · Cited by 358 · cited 2×
“Type I binding spectra occur when the substrate (or other molecules) displaces the water molecule coordinated as the sixth ligand to the low-spin hexa-coordinated heme prosthetic group, causing the heme to adopt the high-spin penta-coordinated conformation (11).”
BackgroundFranz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
BackgroundSelf-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292 · cited 2×
“ylergosta-3,6-diol after azole exposure (16, 32, 54).”
BackgroundXiao, L., Madison, V., Chau, A. S., Loebenberg, D., Palermo, R. E., & McNicholas, P. M. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.2.568-574.2004 · Cited by 267 · cited 1×
“These long secondary side chains interact with the hydrophobic amino acid residues lining the CaCYP51 substrate access channel, and such interactions have been modeled (20, 55).”
BackgroundYuzo, Y., & Yuri, A. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90694-0 · Cited by 245
Ligand interactions with cytochrome P-450. I. Binding of primary amines
Jefcoate, C. R. E., Gaylor, J. L., & Calabrese, R. L. (1969) · Biochemistry · doi:10.1021/bi00836a049 · Cited by 223
Sanati, H., Belanger, P., Fratti, R., & Ghannoum, M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2492 · Cited by 221
Bellamine, A., Mangla, A. T., Nes, W. D., & Waterman, M. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.8937 · Cited by 220 · cited 4×
“tuberculosis CYP51 (1 M) (5) and 23-fold greater than for human CYP51 (0.”
BackgroundMethodInfluentialSelf-citationLamb, D. C., Kelly, D. E., Schunck, W.-H., Shyadehi, A. Z., Akhtar, M., Lowe, D. J., Baldwin, B. C., & Kelly, S. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5682 · Cited by 193 · cited 4×
“(19), and the Ki constants derived for the inhibition of the sterol demethylase reaction (22) of 20 and 30 nM for ketoconazole and fluconazole.”
BackgroundResultInfluentialSelf-citationDiethylcarbamazine-related antimicrobial activity in Mycobacterium tuberculosis-infected blood
Kitchen, L. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.2.241 · Cited by 183
Primary Structure of the P450 Lanosterol Demethylase Gene from Saccharomyces cerevisiae
KALB, V. F., WOODS, C. W., TURI, T. G., DEY, C. R., SUTTER, T. R., & LOPER, J. C. (1987) · DNA · doi:10.1089/dna.1987.6.529 · Cited by 176 · cited 1×
“CYP51 has been shown to be essential for viability in Saccharomyces cerevisiae (14).”
BackgroundErgosterol biosynthesis pathway in Aspergillus fumigatus
Alcazar-Fuoli, L., Mellado, E., Garcia-Effron, G., Lopez, J. F., Grimalt, J. O., Cuenca-Estrella, J. M., & Rodriguez-Tudela, J. L. (2008) · Steroids · doi:10.1016/j.steroids.2007.11.005 · Cited by 162 · cited 1×
“pergillus fumigatus (1) and as the major sterol CYP51 substrate seen under azole”
BackgroundEstabrook, R. W., Peterson, J., Baron, J., & Hildebrandt, A. (1972) · Physical Methods · doi:10.1007/978-1-4757-0196-8_9 · Cited by 160 · cited 2×
“monoxide difference spectra (8) were used to determine native cytochrome P450 concentrations based on an extinction coefficient of 91 mM 1 cm 1 (38) from the”
BackgroundMethodResistance to fluconazole and amphotericin in Candida albicans from AIDS patients
Kelly, S. L., Lamb, D. C., Kelly, D. E., Loeffler, J., & Einsele, H. (1996) · The Lancet · doi:10.1016/s0140-6736(05)65949-1 · Cited by 149 · cited 1×
“ylergosta-3,6-diol after azole exposure (16, 32, 54).”
Self-citationShyadehi, A. Z., Lamb, D. C., Kelly, S. L., Kelly, D. E., Schunck, W.-H., Wright, J. N., Corina, D., & Akhtar, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12445 · Cited by 146 · cited 2×
“lated by PCR from the CYP51 cDNA in YEp51 (48) and, as for the first”
MethodSelf-citationMolecular analysis of cyp51 from fluconazole-resistant Candida albicans strains
Löffler, J., Kelly, S. L., Hebart, H., Schumacher, U., Lass-Flörl, C., & Einsele, H. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb12580.x · Cited by 143 · cited 2×
“ylergosta-3,6-diol after azole exposure (16, 32, 54).”
BackgroundSelf-citationLepesheva, G. I., Ott, R. D., Hargrove, T. Y., Kleshchenko, Y. Y., Schuster, I., Nes, W. D., Hill, G. C., Villalta, F., & Waterman, M. R. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.10.011 · Cited by 140 · cited 1×
“soma brucei and Trypanosoma cruzi CYP51 proteins (18, 25) to”
BackgroundSelf-citationMast, N., White, M. A., Bjorkhem, I., Johnson, E. F., Stout, C. D., & Pikuleva, I. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803717105 · Cited by 133 · cited 3×
“The water molecule may not be expelled from CYP51 proteins by the sub- strate but only slightly shifted to one side, as observed in CYP46A1 (35).”
BackgroundInvasive candidiasis in immunocompromised hospitalized patients.
Sims, C. R., Ostrosky-Zeichner, L., & Rex, J. H. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.05.015 · Cited by 124 · cited 1×
“albicans strains and other Candida species has become an increasing problem, especially among hospitalized immunocompromised patients, such as HIV and AIDS, cancer, and transplant patients, leading to a growing need to develop new effective antifungal strategies against drug-resistant strains (41, 45, 49).”
BackgroundMolecular analysis of cyp51 from fluconazole-resistant Candida albicans strains
Löffler, J. (1997) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(97)00172-9 · Cited by 119
Lepesheva, G. I., Park, H.-W., Hargrove, T. Y., Vanhollebeke, B., Wawrzak, Z., Harp, J. M., Sundaramoorthy, M., Nes, W. D., Pays, E., Chaudhuri, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067470 · Cited by 116 · cited 2×
“The use of C-terminal histidine extensions to facilitate protein purification by Ni(2) -NTA–agarose is commonplace among published cytochrome P450 protein studies, with the C-terminal histidine extension considered not to alter the properties of the protein or structure (3, 26, 27, 35).”
BackgroundSelf-citationXu, Y., Chen, L., & Li, C. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn015 · Cited by 104 · cited 1×
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
BackgroundGenetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei
Fukuoka, T., Johnston, D. A., Winslow, C. A., de Groot, M. J., Burt, C., Hitchcock, C. A., & Filler, S. G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1213-1219.2003 · Cited by 96 · cited 1×
“1), which results in stronger hydrophobic interactions with the aromatic amino acids lining the substrate binding pocket (10).”
BackgroundChanges in susceptibility to posaconazole in clinical isolates of Candida albicans
Li, X. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh027 · Cited by 96 · cited 1×
“By building on this comprehensive investigation of clinically relevant azoles and their binding properties to purified wild-type CaCYP51, we are currently investigating the effects of CaCYP51 point mutations associated with azole resistance (9, 30, 32, 34, 47, 54, 56).”
BackgroundTrösken, E. R., Adamska, M., Arand, M., Zarn, J. A., Patten, C., Völkel, W., & Lutz, W. K. (2006) · Toxicology · doi:10.1016/j.tox.2006.08.007 · Cited by 95 · cited 4×
“agreement with previous in vitro CYP51 activity studies using purified CaCYP51 and microsomal protein fractions (4, 19, 22, 23, 50).”
BackgroundResultInfluentialExpression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase
Lutz, J. D., Dixit, V., Yeung, C. K., Dickmann, L. J., Zelter, A., Thatcher, J. E., Nelson, W. L., & Isoherranen, N. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.10.012 · Cited by 88 · cited 5×
“Amax and Kd values were derived from mean data sets of three replicates by using a rearrangement of the Morrison equation (33).”
MethodInfluentialLepesheva, G. I., Virus, C., & Waterman, M. R. (2003) · Biochemistry · doi:10.1021/bi034663f · Cited by 80 · cited 1×
“The relatively small change in spin state caused by the binding of lanosterol was previously observed for other CYP51 enzymes (2, 5, 28), with spin state changes generally not exceeding 10%.”
BackgroundLamb, D. C., Kelly, D. E., Waterman, M. R., Stromstedt, M., Rozman, D., & Kelly, S. L. (1999) · Yeast · doi:10.1002/(sici)1097-0061(19990630)15:9<755::aid-yea417>3.0.co;2-8 · Cited by 80
CYP51 from Trypanosoma brucei Is Obtusifoliol-Specific
Lepesheva, G. I., Nes, W. D., Zhou, W., Hill, G. C., & Waterman, M. R. (2004) · Biochemistry · doi:10.1021/bi048967t · Cited by 79
Self-citationLocuson, C. W., Hutzler, J. M., & Tracy, T. S. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012609 · Cited by 79 · cited 1×
“A lower Amax value suggests suboptimal coordination orientation or hindered binding (31) of the triazoles relative to the imidazole antifungals, although the inherent field strength of the ligand will also affect the observed intensity and wavelength of the spectrum.”
BackgroundPodust, L. M., von Kries, J. P., Eddine, A. N., Kim, Y., Yermalitskaya, L. V., Kühne, R., Ouellet, H., Warrier, T., Alteköster, M., Lee, J. S., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00311-07 · Cited by 79 · cited 2×
“on Mycobacterium tuberculosis CYP130 and CYP51 (42, 43)”
BackgroundAoyama, Y., Yoshida, Y., Sonoda, Y., & Sato, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)75777-9 · Cited by 76 · cited 1×
“The relatively small change in spin state caused by the binding of lanosterol was previously observed for other CYP51 enzymes (2, 5, 28), with spin state changes generally not exceeding 10%.”
BackgroundThe biodiversity of microbial cytochromes P450
Kelly, S. L., Lamb, D. C., Jackson, C. J., Warrilow, A. G. S., & Kelly, D. E. (2003) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/s0065-2911(03)47003-3 · Cited by 75 · cited 1×
“Fungal sterol 14- demethylase (CYP51) is required for ergosterol biosynthesis, an ancestral activity in the cytochrome P450 (CYP) superfamily of hemoproteins, and is the main target for azole antifungal drugs (15).”
BackgroundSelf-citationGenetic Analysis of Azole Resistance in the Darlington Strain of Candida albicans
Kakeya, H., Miyazaki, Y., Miyazaki, H., Nyswaner, K., Grimberg, B., & Bennett, J. E. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.2985-2990.2000 · Cited by 75 · cited 2×
“This 4-fold difference in MIC values (13) was not reflected in the IC50 results per se (Fig.”
BackgroundResultVenkateswarlu, K., Denning, D. W., Manning, N. J., & Kelly, S. L. (1995) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1995.tb07797.x · Cited by 67 · cited 1×
“albicans cell extracts (51) previously indicated that itraconazole was 4-fold more effective as an inhibitor of CYP51 activity than fluconazole, in contrast to the 2-fold differences in”
ResultSelf-citationDifferential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents
Lamb, D. C., Kelly, D. E., Baldwin, B. C., & Kelly, S. L. (2000) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00169-6 · Cited by 62 · cited 1×
“(21) for itraconazole and ketoconazole, the IC50 of 30 nM determined for fluconazole by Kudo et al.”
BackgroundSelf-citationVenkateswarlu, K., Lamb, D. C., Kelly, D. E., Manning, N. J., & Kelly, S. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.8.4492 · Cited by 58 · cited 1×
“ductase (52), 3 U yeast glucose-6-phosphate dehydrogenase, 2 mol disodium”
BackgroundSelf-citationBellamine, A., Lepesheva, G. I., & Waterman, M. R. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m400239-jlr200 · Cited by 54 · cited 4×
“Previous work (4, 27) also used a fourhistidine tag.”
MethodResultInfluentialCytochrome P450 2C9 Type II Binding Studies on Quinoline-4-Carboxamide Analogues
Peng, C.-C., Cape, J. L., Rushmore, T. H., Crouch, G. J., & Jones, J. P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8011257 · Cited by 50 · cited 1×
“(40) screened for CYP2C9 drug interactions with quinoline-4-carboxamide analogues by using both UV-Vis spectral analysis and lanosterol demethylase IC50 determinations.”
MethodParker, J. E., Merkamm, M., Manning, N. J., Pompon, D., Kelly, S. L., & Kelly, D. E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-08 · Cited by 46 · cited 2×
“Azole inhibitors that are selective for the fungal enzyme over the human homologue have been developed and are commonly used to treat fungal infections, including those caused by Candida albicans (23, 39).”
BackgroundSelf-citationArase, M., Waterman, M. R., & Kagawa, N. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.067 · Cited by 45 · cited 3×
“The use of C-terminal histidine extensions to facilitate protein purification by Ni(2) -NTA–agarose is commonplace among published cytochrome P450 protein studies, with the C-terminal histidine extension considered not to alter the properties of the protein or structure (3, 26, 27, 35).”
BackgroundMethodLepesheva, G. I., Podust, L. M., Bellamine, A., & Waterman, M. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102767200 · Cited by 45 · cited 3×
“Previous work (4, 27) also used a fourhistidine tag.”
BackgroundMethodResultDifferential inhibition of Candida albicans CYP51 with azole antifungal stereoisomers
Lamb, D. C., Kelly, D. E., Baldwin, B. C., Gozzo, F., Boscott, P., Richards, W. G., & Kelly, S. L. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb10303.x · Cited by 36 · cited 1×
“These long secondary side chains interact with the hydrophobic amino acid residues lining the CaCYP51 substrate access channel, and such interactions have been modeled (20, 55).”
BackgroundSelf-citationInteraction of Mycobacterium tuberculosis CYP130 with Heterocyclic Arylamines
Podust, L. M., Ouellet, H., von Kries, J. P., & de Montellano, P. R. O. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017632 · Cited by 35 · cited 2×
“on Mycobacterium tuberculosis CYP130 and CYP51 (42, 43)”
BackgroundKonkle, M. E., Hargrove, T. Y., Kleshchenko, Y. Y., von Kries, J. P., Ridenour, W. B., Uddin, M. J., Caprioli, R. M., Marnett, L. J., Nes, W. D., Villalta, F., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801643b · Cited by 34 · cited 1×
“soma brucei and Trypanosoma cruzi CYP51 proteins (18, 25) to”
BackgroundSelf-citationde Melo, N. R., Moran, G. P., Warrilow, A. G. S., Dudley, E., Smith, S. N., Sullivan, D. J., Lamb, D. C., Kelly, D. E., Coleman, D. C., & Kelly, S. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00446-08 · Cited by 34 · cited 1×
“albicans also has other CYPs that can bind antifungal azoles within the cell (36).”
BackgroundSelf-citationKudo, M., Ohi, M., Aoyama, Y., Nitahara, Y., Chung, S.-K., & Yoshida, Y. (2005) · The Journal of Biochemistry · doi:10.1093/jb/mvi073 · Cited by 27 · cited 3×
“(19), and the Ki constants derived for the inhibition of the sterol demethylase reaction (22) of 20 and 30 nM for ketoconazole and fluconazole.”
BackgroundMethodResultWarrilow, A. G. S., Jackson, C. J., Parker, J. E., Marczylo, T. H., Kelly, D. E., Lamb, D. C., & Kelly, S. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01237-08 · Cited by 21 · cited 4×
“Addition of 88 M lanosterol caused a 14.5% change in spin state of CaCYP51, based on an extinction coefficient of 118 mM 1 cm 1 for the difference spectrum ( A) with CYP164A2 (53), while addition of 88 M eburicol induced a spin state change of 2.3%.”
BackgroundInfluentialSelf-citationThree-Dimensional Quantitative Structure-Activity Relationship Analysis of Human CYP51 Inhibitors
Ekins, S., Mankowski, D. C., Hoover, D. J., Lawton, M. P., Treadway, J. L., & Harwood, H. J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.013888 · Cited by 20 · cited 2×
“cerevisiae and human CYP51 were 5 M (17) and 30 M (7), respectively.”
BackgroundKitahama, Y., Nakamura, M., Yoshida, Y., & Aoyama, Y. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.558 · Cited by 10 · cited 1×
“cerevisiae and human CYP51 were 5 M (17) and 30 M (7), respectively.”
Background
Cited by
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
“Adverse events associated with the various triazoles([1-4,24-26,31,32])”
BackgroundBecher, R., & Wirsel, S. G. R. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4195-9 · Cited by 245
“…Park et al. 2011), F145L (Bellamine et al. 2004; Kudo et al. 2005), T315A (Lamb et al. 1997), G464S (Kelly et al. 1999), R467K (Lamb et al. 2000; Park et al. 2011; White 1997), I471T (Warrilow et al. 2010), or multiple substitutions (Bellamine et al. 2004; Kudo et al. 2005; Marichal et al. 1999).”
BackgroundInfluentialFlowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239
“Point mutations in the ERG11 gene result in reduced binding affinity of azoles to their target without precluding enzymatic function (31).”
Background
Metadata
- Authors
- Warrilow, A. G. S., Martel, C. M., Parker, J. E., Melo, N., Lamb, D. C., Nes, W. D., Kelly, D. E., & Kelly, S. L.
- Affiliations
- Swansea University (GB)
- Texas Tech University (US)
- Corresponding author
- Kelly, Steven L.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-10
- Volume
- 54
- Issue
- 10
- Pages
- 4235-4245
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC2944560
- OpenAlex
- W2101970140
- Cited by
- 112
- References
- 60
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 4 · 2014: 8 · 2013: 9 · 2012: 6
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida albicans, sterol 14α-demethylase, CYP51, lanosterol, fluconazole, itraconazole, voriconazole, ketoconazole, clotrimazole, econazole, miconazole, CO displacement, enzyme kinetics, antifungal resistance, fluconazole resistance, antifungal drug screening
- MeSH terms
- Antifungal Agents, Azoles, Candida albicans, Econazole, Ketoconazole, Miconazole, Protein Binding, Pyrimidines, Triazoles, Fluconazole, Itraconazole, Sterol 14-Demethylase, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.